Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 1401 - 1425 of 1967 in total

Afoxolaner

Experimental
Vet approved
Matched Iupac: … 2-[(4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl}naphthalen …
Matched Mixtures name: … Nexgard Spectra 38mg/8mg Chewable Tablets for Dogs >7.5-15kg ... Nexgard Spectra 9mg/2mg Chewable Tablets for Dogs 2-3.5kg ... Nexgard Spectra 19mg/4mg Chewable Tablets for Dogs >3.5-7.5kg …
Matched Products: … NexGard 11mg chewable tablets for dogs 2-4kg ... NexGard 136mg chewable tablets for dogs > 25-50kg ... NexGard 28mg chewable tablets for dog > 4-10kg …

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Alimentary Tract and Metabolism ... Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins …
Matched Products: … REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML …

Risankizumab

Risankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23). It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab...
Approved
Investigational
Matched Description: … It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and ... [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease. ... [L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716] …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Skin and Mucous Membrane Agents …
Matched Products: … SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 75MG/0.83ML ... SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 150MG/ML …

Letermovir

Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status...
Approved
Investigational
Matched Iupac: … 2-[(4S)-8-fluoro-3-[2-methoxy-5-(trifluoromethyl)phenyl]-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3,4-dihydroquinazolin …
Matched Description: … [A31290] Letermovir has recieved both priority and orphan drug status from the FDA. ... Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus …
Matched Categories: … Antivirals for Systemic Use ... Antiinfectives for Systemic Use …
Matched Products: … PREVYMIS CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML ... PREVYMIS 240mg/12mL (20mg/mL) concentrate for solution for infusion ... PREVYMIS 480mg/24mL (20mg/mL) concentrate for solution for infusion …

Avibactam

Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens,...
Approved
Matched Description: … As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 ... infections in combination with metronidazole, and the treatment of complicated urinary tract infections ... This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal …
Matched Products: … ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5G …

3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide

Experimental
Matched Name: … 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl …
Matched Iupac: … 3-(3,5-dibromo-4-hydroxybenzoyl)-2-ethyl-N-{4-[(1,3-thiazol-2-yl)sulfamoyl]phenyl}-1-benzofuran-6-sulfonamide …

4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide

Experimental
Matched Name: … 4-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamide …
Matched Iupac: … 4-[(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}-1H-1,3-benzodiazol-6-yl)oxy]-N-methylpyridine-2-carboxamide …

3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide

Experimental
Matched Name: … 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide …
Matched Iupac: … 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide …

2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide

Experimental
Matched Name: … 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide …
Matched Iupac: … 2-amino-4-{2,4-dichloro-5-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide …

(2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL

Experimental
Matched Name: … (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL …
Matched Iupac: … (2R,3R,4S)-3-(4-hydroxyphenyl)-4-methyl-2-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-3,4-dihydro-2H-1-benzopyran …

1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1-DIOL

Experimental
Matched Name: … 1-[3-({[(4-AMINO-5-FLUORO-2-METHYLQUINOLIN-3-YL)METHYL]THIO}METHYL)PHENYL]-2,2,2-TRIFLUOROETHANE-1,1- …
Matched Iupac: … 1-[3-({[(4-amino-5-fluoro-2-methylquinolin-3-yl)methyl]sulfanyl}methyl)phenyl]-2,2,2-trifluoroethane- …

Tetrofosmin

Tetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds. It presents a molecular formula of 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane. Tetrofosmin is part of the group of diphosphines. Tetrofosmin is used in conjunction with technetium Tc-99m as a radiopharmaceutical.
Approved
Matched Products: … MYOVIEW POWDER FOR INJECTION ... MYOVIEW FOR INJECTION 0.23 mg/vial …

Olipudase alfa

Olipudase alfa is recombinant human acid sphingomyelinase. It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease. ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency...
Approved
Investigational
Matched Description: … [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid ... storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and ... to hydrolyze sphingomyelin accumulated in body tissues, such as the lungs, liver, spleen, kidneys, and …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Enzymes and Coenzymes …
Matched Products: … XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION …

Hydrocortisone succinate

Approved
Matched Categories: … Hydrocortisone and derivatives ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Matched Products: … SOLU-CORTEF FOR INJECTION 100 mg/vial ... Hydrocortisone Sodium Succinate for Injection ... HYDROCORTISONE SODIUM SUCCINATE FOR INJECTION B. P …

Trastuzumab deruxtecan

Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of...
Approved
Investigational
Matched Description: … The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from ... A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and ... Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL …

Sodium glycerophosphate

Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body . The extent of this reaction is dependent on the activity of serum alkaline phosphatases.
Approved
Matched Description: … Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. …
Matched Mixtures name: … Vitamin and Mineral Supplement - Liq ... Hemarexin Liquid and Drinkable Ampoules ... OLIMEL N7E, emulsion for infusion …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …
Matched Products: … GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216 mg/ml ... Glycophos Concentrate for Solution for Infusion 216mg/ml …

Anifrolumab

Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.[A237074,L34929] The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying antirheumatic drugs like methotrexate.[A237079,L34929] Three...
Approved
Investigational
Matched Description: … [hydroxychloroquine], glucocorticoids like [dexamethasone], and disease modifying antirheumatic drugs ... [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that ... The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Matched Products: … SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSION …

Obinutuzumab

Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … GAZYVA 1000 MG/ 40 ML CONCENTRATE FOR SOLUTION FOR INFUSION ... GAZYVA CONCENTRATE FOR SOLUTION FOR INFUSION 1000MG/40ML …

Necitumumab

Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and...
Approved
Investigational
Matched Description: … Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment ... It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands ... , a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50ML …

Eptinezumab

Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP).[F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment...
Approved
Investigational
Matched Description: … [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human ... Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed ... [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Products: … VYEPTI CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/ML …

Amivantamab

Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose...
Approved
Investigational
Matched Description: … [A235103,L34193] Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually ... FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and ... Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Matched Products: … RYBREVANT 350mg/7mL Concentrate for Solution for Infusion …

Galcanezumab

Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin gene-related peptide (CGRP). Although several small-molecule CGRP receptor antagonists have been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to selectively bind to CGRP entities with high potency. Given this target specificity, lack of...
Approved
Investigational
Matched Description: … [A33112] Galcanezumab was approved by the FDA in September 2018, and is indicated for the preventive ... Galcanezumab is a humanized monoclonal antibody developed by Eli Lilly and Company against human calcitonin ... promising safety and tolerability. …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Matched Products: … EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED PEN 120 MG/ML ... Pontevia 120 mg solution for injection in pre-filled pen ... EMGALITY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100 MG/ML …

Daunorubicin

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
Approved
Matched Description: … , used in treatment of leukemia and other neoplasms. ... A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... cytarabine and daunorubicin ... Cytotoxic Antibiotics and Related Substances …
Matched Products: … DAUNOCIN FOR INJ ... DAUNOCIN FOR INJECTION 20 mg/vial ... DAUNOBLASTINA FOR INJECTION 20 mg/vial …

Decitabine

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis.[A215082, A215092] Among treatment options, nucleoside analogues such as...
Approved
Investigational
Matched Description: … approved by the FDA for the treatment of MDS on February 5, 2006. ... presentation, including neutropenia and thrombocytopenia. ... syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides ... Nucleic Acid Synthesis Inhibitors …
Matched Products: … DACOGEN (Decitabine) 50 mg Powder for Concentrate for Solution for Infusion ... Redtibin (Decitabine) Powder for Injection 50mg/vial …

Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate

This solid compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. This substance targets the protein interleukin-2.
Experimental
Matched Name: … Methyl (2S)-2-[[2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetyl]amino]-3-[4-(2-phenylethynyl)phenyl]propanoate …
Matched Iupac: … methyl (2S)-2-{2-[(3R)-1-carbamimidoylpiperidin-3-yl]acetamido}-3-[4-(2-phenylethynyl)phenyl]propanoate …
Matched Description: … The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. …
Displaying drugs 1401 - 1425 of 1967 in total